seperator

Management Team

seperator

PD Dr. Carsten Rudolph

Prof. Dr. Christian Plank

Dr. med. Thomas Langenickel

Dr. Christian Wawrzinek

 

PD Dr. Carsten Rudolph

Prof. Dr. Christian Plank

Dr. med. Thomas Langenickel

 

seperator

PD DR. CARSTEN RUDOLPH

seperator

Chief Executive Officer

Dr. Carsten Rudolph, PhD is a co-founder of Ethris and the lead inventor of its SNIM® RNA Technology. His deep expertise is delivering mRNA specifically to the lungs. He is the inventor of 15 patents/applications and has authored more than 120 scientific publications. Carsten is affiliated with the Dr. von Haunerschen Kinderhospital of the Ludwig Maximilians University (LMU) in Munich. He obtained his pharmaceutical degree from Freie Universität (FU) Berlin.

seperator

PD DR. CARSTEN RUDOLPH

seperator

Chief Executive Officer

Dr. Carsten Rudolph, PhD is a co-founder of Ethris and the lead inventor of its SNIM® RNA Technology. His deep expertise is delivering mRNA specifically to the lungs. He is the inventor of 15 patents/applications and has authored more than 120 scientific publications. Carsten is affiliated with the Dr. von Haunerschen Kinderhospital of the Ludwig Maximilians University (LMU) in Munich. He obtained his pharmaceutical degree from Freie Universität (FU) Berlin.

seperator

PROF. DR. CHRISTIAN PLANK

seperator

Chief Technology Officer

Prof. Dr. Christian Plank, PhD is a co-founder of Ethris and brings a broad expertise in targeted drug delivery. He is the author of more than 170 publications and co-inventor of numerous patents in the field of nucleic acid delivery. Christian is a Professor at the Technical University of Munich and obtained his PhD in biochemistry from the University of Vienna, Austria.

seperator

DR. MED. THOMAS LANGENICKEL

seperator

Chief Medical Officer

Dr. med. Thomas Langenickel, MD, has more than 15 years of experience in clinical development and translational medicine in cardiovascular and respiratory disease areas. He previously held the position of Executive Director and Head of Respiratory Profiling at Novartis AG and served as Medical Director at Bristol-Myers Squibb. He obtained his MD and PhD at the Humboldt University of Berlin, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the Max-Delbrück Center for Molecular Medicine and the Charité Hospital in Berlin, Germany. He previously completed a post-doctoral fellowship at the National Heart, Lung and Blood Institute in Bethesda, USA.

seperator

DR. MED. THOMAS LANGENICKEL

seperator

Chief Medical Officer

Dr. med. Thomas Langenickel, MD, has more than 15 years of experience in clinical development and translational medicine in cardiovascular and respiratory disease areas. He previously held the position of Executive Director and Head of Respiratory Profiling at Novartis AG and served as Medical Director at Bristol-Myers Squibb. He obtained his MD and PhD at the Humboldt University of Berlin, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the Max-Delbrück Center for Molecular Medicine and the Charité Hospital in Berlin, Germany. He previously completed a post-doctoral fellowship at the National Heart, Lung and Blood Institute in Bethesda, USA.

seperator

DR. CHRISTIAN WAWRZINEK

seperator

Chief Corporate Strategy Officer

Dr. Christian Wawrzinek, PhD is a hands-on serial entrepreneur and investor, focusing on companies with world-changing potential in Biotech, Tech and AI. He has founded and built-up several successful companies that have together generated a total turnover of over 1 billion US dollars. For his entrepreneurial achievements he has won several prizes, including the renowned “Entrepreneur of The Year” Award by EY and the Deloitte Technology Fast 50 Award for the fastest-growing German Tech company with over 28.000% 5-year revenue growth. In 2018, he took one of his companies public indirectly, via a EUR 270M reverse-IPO to Nasdaq Nordic. Christian obtained his dental medicine degree in 2005 and in 2008 his PhD with “magna cum laude” from Christian-Albrechts-University zu Kiel.

Join the Team.

CONTACT